Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €32.48 EUR
Change Today -0.33 / -1.01%
Volume 54.2K
ALCLS On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
NASDAQ GM
OTC US
Frankfurt
As of 11:38 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Open
€33.23
Previous Close
€32.81
Day High
€33.48
Day Low
€32.42
52 Week High
05/29/15 - €41.77
52 Week Low
10/8/14 - €8.28
Market Cap
1.1B
Average Volume 10 Days
128.1K
EPS TTM
€-0.04
Shares Outstanding
35.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors for the treatment of cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications. It has strategic alliances with Les Laboratoires Servier SAS to develop and commercialize product candidates targeting leukemia and solid tumors; and Pfizer Inc. to generate CAR T-cells in the field of oncology. Cellectis was founded in 1999 and is based in Paris, France.

89 Employees
Last Reported Date: 03/26/15
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €328.4K
Co-Founder, Executive Vice President of Corpo...
Total Annual Compensation: €248.8K
Compensation as of Fiscal Year 2013.

cellectis (ALCLS) Key Developments

Cellectis S.A. expected to report First-Half, 2015 results on July 29, 2015. This event was calculated by Capital IQ (Created on July 23, 2015).

Cellectis S.A. expected to report First-Half, 2015 results on July 29, 2015. This event was calculated by Capital IQ (Created on July 23, 2015).

Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-Cell Immunotherapies

Cellectis announced the publication of a study in Cancer Research describing the applicability of TALEN®-mediated genome editing to a scalable process, which enables the manufacturing of third-party CAR T-cell immunotherapies. Adoptive immunotherapy using autologous T-cells endowed with chimeric antigen receptors or CARs has emerged as a powerful means of treating cancer. However, a limitation of this approach is that autologous CAR T-cells must be generated on a custom-made basis. To overcome the limitations of patient-derived CAR T-cell therapies, TALEN® mediated gene inactivation can be used to generate non-alloreactive T-cells from third-party donors in a robust, scalable manufacturing process, thus allowing "off-the-shelf" CAR T-cell immunotherapies. Laurent Poirot Ph.D. and his collaborators use this TALEN®-mediated editing approach to develop a process for the large-scale manufacturing of T-cells deficient in expression of both their T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. Functionally, T-cells manufactured with this process do not mediate graft-versus-host reactions, and are rendered resistant to destruction by alemtuzumab. These characteristics enable the administration of alemtuzumab concurrently or prior to engineered T-cells, supporting their engraftment. Furthermore, endowing the TALEN®-engineered cells with a CD19 CAR led to efficient destruction of CD19+ tumor targets even in the presence of the chemotherapeutic agent. CAR T-cell immunotherapies can therefore be used in an “off-the-shelf” manner akin to other biological immunopharmaceuticals.

Cellectis S.A. Presents at French Life Science Days conference, Jun-17-2015

Cellectis S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €32.48 EUR -0.33

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.26 USD +0.16
Lonza Group AG SFr.140.40 CHF +4.10
Sangamo BioSciences Inc $8.91 USD -0.29
Sigma-Aldrich Corp $139.58 USD -0.06
View Industry Companies
 

Industry Analysis

ALCLS

Industry Average

Valuation ALCLS Industry Range
Price/Earnings 89.0x
Price/Sales 33.6x
Price/Book 3.9x
Price/Cash Flow 115.8x
TEV/Sales 33.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit www.cellectis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.